ArticleCommunications medicine2024

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.

Reagan M Barnett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.